Among synthesized REN analogs (Figure 4), NZ51 suppresses ATPase/helicase of DDX3 at low micromole concentration in vitro and displays antiproliferative activity, blocking cell replication at the G1 phase of aggressive breast cancer in different cell cultures [43], causing a global delay in cell cycle progression [135]. Here, DDX3X is linked to breast cancer.